Have a personal or library account? Click to login
Hypereosinophilia: Clinical Presentations and Diagnostic Distinction Between Syndromic and Reactive Entities – A Case Series Cover

Hypereosinophilia: Clinical Presentations and Diagnostic Distinction Between Syndromic and Reactive Entities – A Case Series

Open Access
|Dec 2025

References

  1. Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 2017;92(11):1243–59.
  2. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968;68(6):1220–9.
  3. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54(1):1–27.
  4. Roufosse F. Clinical and biological markers to monitor treatment response in hypereosinophilic syndromes. Front Med (Lausanne) 2017;4:240.
  5. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the FIP1L1 and PDGFRA genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348(13):1201–14.
  6. Ogbogu PU, Rosing DR, Horne MK. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27(3):457–75.
  7. Klion AD. How I treat hypereosinophilic syndromes. Blood 2015;126(9):1069–77.
  8. Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood 2017;129(6):704–14.
  9. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 1985;102(1):109–14.
  10. Alfaro TM, Bernardo JE, Sá-Sousa A, et al. Gastrointestinal involvement in hypereosinophilic syndromes. GE Port J Gastroenterol 2016;23(5):252–7.
  11. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009;124(6):1319–25.
  12. Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol 2010;126(1):39–44.
  13. Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 2010;126(1):179–81.
  14. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83(10):2759–79.
  15. Simon HU, et al. Eosinophils and infection. Swiss Med Wkly 2011;141:w13325.
  16. Kersh AE, et al. Mucormycosis presenting with marked eosinophilia. Med Mycol Case Rep 2019;25:23–6.
  17. Greco A, et al. Eosinophilic granulomatosis with polyangiitis: evolving concepts. Autoimmun Rev 2015;14:704–11.
  18. Vaglio A, et al. Overlap of HES and ANCA-associated vasculitis. Clin Exp Rheumatol 2013;31(Suppl 75):S98–S101.
  19. Ortega HG, et al. Severe eosinophilic asthma. N Engl J Med 2014;371:1198–207.
  20. Alfadda AA, et al. Eosinophilic gastroenteritis: an overlooked cause of abdominal pain. Saudi J Gastroenterol 2011;17:199–203.
  21. Talley NJ, Shorter RG, Phillips SF, Zinsmeister AR. Eosinophilic gastroenteritis: a clinicopathologic study. Gut 1990;31:54–8.
  22. Rothenberg ME, et al. Treatment of hypereosinophilic syndromes with mepolizumab. N Engl J Med 2008;358:1215–28.
DOI: https://doi.org/10.2478/rjim-2025-0024 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Language: English
Submitted on: Oct 6, 2025
|
Published on: Dec 24, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Ashaq Hussain Parrey, Basharat Kassana, Hilal Bhat, Mohd. Ismail, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

AHEAD OF PRINT